Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

YU Lu; WU Xudong; ZHANG Ming

doi:10.6039/j.issn.1001-0408.2025.07.15

您当前的位置：

首页 >

文章列表页 >

Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

更新时间：2025-09-23

- Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease
- ZHONGGUO YAOFANG Vol. 36, Issue 7, Pages: 853-857(2025)
- 作者机构：
  
  1.宁波市鄞州区第二医院临床药学部，浙江宁波　315100
  2.宁波市鄞州区第二医院医共体钟公庙分院内科，浙江宁波　315100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.07.15
  CLC： R969.3
- Received：04 September 2024，
  
  Revised：2025-02-04，
  
  Accepted：07 February 2025，
  
  Published：15 April 2025
- 稿件说明：
移动端阅览
俞璐,吴旭栋,张明.乳腺癌伴慢性肾脏病患者的个体化治疗与药学监护 [J].中国药房,2025,36(07):853-857.

YU Lu,WU Xudong,ZHANG Ming.Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease[J].ZHONGGUO YAOFANG,2025,36(07):853-857.
俞璐,吴旭栋,张明.乳腺癌伴慢性肾脏病患者的个体化治疗与药学监护 [J].中国药房,2025,36(07):853-857. DOI： 10.6039/j.issn.1001-0408.2025.07.15.

YU Lu,WU Xudong,ZHANG Ming.Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease[J].ZHONGGUO YAOFANG,2025,36(07):853-857. DOI： 10.6039/j.issn.1001-0408.2025.07.15.

摘要

目的

为乳腺癌伴慢性肾脏病（CKD）患者的个体化治疗和临床药学实践提供参考。

方法

临床药师参与1例乳腺癌伴CKD患者的抗肿瘤治疗过程并提供药学监护。临床药师查阅指南与文献，协助医生制定术前初始新辅助化疗方案（多西他赛+曲妥珠单抗+帕妥珠单抗），并就方案所含药物可能引发的呕吐、骨髓抑制、肾功能损害、心脏毒性等不良反应提出监护建议；针对患者治疗后出现的急性肾损伤，临床药师通过关联性评价协助医生分析不良反应产生原因，并结合患者意愿，将多西他赛替换为紫杉醇（无需根据肾功能调整剂量）；临床药师协助医生确定术后靶向治疗方案（曲妥珠单抗+帕妥珠单抗），考虑到患者为雌激素受体阳性，建议其在放疗结束后规律服用阿那曲唑并定期检测骨密度。

结果

医生接受临床药师建议。患者顺利完成术前新辅助化疗和术后靶向治疗，带药（阿那曲唑）出院；治疗期间，未出现骨髓抑制、心脏毒性等不良反应，后续也未发生骨质疏松。

结论

临床药师根据患者肾功能分析调整术前/术后抗肿瘤治疗方案，及时评估抗肿瘤药物与急性肾损伤的关联性，积极开展全流程药学监护，保障了乳腺癌伴CKD患者的用药安全。

Abstract

OBJECTIVE

To provide a reference for individualized treatment and pharmaceutical care for patients with breast cancer complicated with chronic kidney disease （CKD）.

METHODS

Clinical pharmacists participated in the anti-tumor treatment and pharmaceutical care for a breast cancer patient with CKD. Clinical pharmacists reviewed guidelines and literature to assist the clinical physician in formulating the initial neoadjuvant treatment plan （docetaxel+trastuzumab+paltuzumab） and provided monitoring recommendations for potential adverse drug reactions， such as vomiting， myelosuppression， renal impairment， cardiotoxicity. In response to the patient’s acute kidney injury after treatment， clinical pharmacists assisted the physician in analyzing the cause of the adverse reaction through causality assessment. Taking into account the patient’s preferences， docetaxel was substituted with paclitaxel （which did not require dose adjustment based on renal function）. The clinical pharmacists collaborated with the physician to establish a postoperative targeted therapy regimen （trastuzumab+pertuzumab）. Taking into account the patient’s positive estrogen receptor status， the clinical pharmacists recommended to initiate regular anastrozole administration after the completion of radiotherapy and undergo periodic bone density assessments.

RESULTS

The clinical physician accepted the suggestions from the clinical pharmacists. The patient successfully completed preoperative neoadjuvant chemotherapy and postoperative targeted therapy， and was discharged with medication （anastrozole）. During the treatment process， the patient did not experience adverse reactions such as myelosuppression， cardiotoxicity， or the occurrence of osteoporosis.

CONCLUSIONS

Clinical pharmacists analyzed and adjusted the preoperative and postoperative antitumor treatment plans based on the patient’s renal function. They promptly assessed the correlation between antitumor drugs and acute kidney injury， and actively implemented comprehensive pharmaceutical care to ensure medication safety for breast cancer patients with CKD.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

MALYSZKO J ， TESAROVA P ， CAPASSO G ， et al . The link between kidney disease and cancer：complications and treatment [J ] . Lancet ， 2020 ， 396 （ 10246 ）： 277 - 287 .

MAGEE C . Kidney disease and death from cancer [J ] . Am J Kidney Dis ， 2014 ， 63 （ 1 ）： 7 - 9 .

US Food and Drug Administration . Pharmacokinetics in patients with impaired renal function：study design，data analysis，and impact on dosing and labeling [EB/OL ] .[ 2024-08-31 ] . https：//www.fda.gov/media/78573/download https://www.fda.gov/media/78573/download .

MODI G ， MADABHAVI I ， PATEL A ， et al . Treatment of breast cancer in a patient of Alport syndrome-induced chronic renal failure：a triumph story [J ] . J Cancer Res Ther ， 2018 ， 14 （ 2 ）： 462 - 464 .

CAI J H ， ZHENG J H ， LIN X Q ， et al . Individualized treatment of breast cancer with chronic renal failure：a case report and review of literature [J ] . World J Clin Cases ， 2021 ， 9 （ 33 ）： 10345 - 10354 .

GRADISHAR W J ， ANDERSON B O ， ABRAHAM J ， et al . Breast cancer，version 3，2020，NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw ， 2020 ， 18 （ 4 ）： 452 - 478 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南：2022 [M ] . 北京：人民卫生出版社， 2022 ： 25 - 30 .

OZOLS R F ， BUNDY B N ， GREER B E ， et al . Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer：a Gynecologic Oncology Group study [J ] . J Clin Oncol ， 2003 ， 21 （ 17 ）： 3194 - 3200 .

CALVERT A H ， NEWELL D R ， GUMBRELL L A ， et al . Carboplatin dosage：prospective evaluation of a simple formula based on renal function [J ] . J Clin Oncol ， 1989 ， 7 （ 11 ）： 1748 - 1756 .

EGORIN M J ， VAN ECHO D A ， TIPPING S J ， et al . Pharmacokinetics and dosage reduction of cis-diammine（1，1-cyclobutane dicarboxylato）-platinum in patients with impaired renal function [J ] . Cancer Res ， 1984 ， 44 （ 11 ）： 5432 - 5438 .

LONGNECKER S M ， DONEHOWER R C ， CATES A E ， et al . High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase Ⅰ trial [J ] . Cancer Treat Rep ， 1987 ， 71 （ 1 ）： 53 - 59 .

TOMITA M ， KURATA H ， AOKI Y ， et al . Pharmacokine- tics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer [J ] . Anticancer Drugs ， 2001 ， 12 （ 5 ）： 485 - 487 .

WATANABE M ， AOKI Y ， TOMITA M ， et al . Paclitaxel and carboplatin combination chemotherapy in a hemo- dialysis patient with advanced ovarian cancer [J ] . Gynecol Oncol ， 2002 ， 84 （ 2 ）： 335 - 338 .

WOO M H ， GREGORNIK D ， SHEARER P D ， et al . Pharmacokinetics of paclitaxel in an anephric patient [J ] . Cancer Chemother Pharmacol ， 1999 ， 43 （ 1 ）： 92 - 96 .

LI Y F ， FU S ， HU W ， et al . Systemic anticancer therapy in gynecological cancer patients with renal dysfunction [J ] . Int J Gynecol Cancer ， 2007 ， 17 （ 4 ）： 739 - 763 .

MICALLEF R A ， BARRETT-LEE P J ， DONOVAN K ， et al . Trastuzumab in patients on heamodialysis for renal failure [J ] . Clin Oncol （R Coll Radiol）， 2007 ， 19 （ 7 ）： 559 .

MCKEAGE K ， PERRY C M . Trastuzumab：a review of its use in the treatment of metastatic breast cancer over- expressing HER2 [J ] . Drugs ， 2002 ， 62 （ 1 ）： 209 - 243 .

GIANNI L ， PIENKOWSKI T ， IM Y H ， et al . 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer （NEOSPHERE）：a multi- centre，open-label，phase 2 randomized trial [J ] . Lancet Oncol ， 2016 ， 17 （ 6 ）： 791 - 800 .

SHAO Z M ， PANG D ， YANG H J ， et al . Efficacy，safety，and tolerability of pertuzumab，trastuzumab，and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia：the PEONY phase 3 randomized clinical trial [J ] . JAMA Oncol ， 2020 ， 6 （ 3 ）： e193692 .

QUARTINO A L ， LI H B ， JIN J Y ， et al . Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [J ] . Cancer Chemother Pharmacol ， 2017 ， 79 （ 2 ）： 353 - 361 .

KEIZER R J ， HUITEMA A D R ， SCHELLENS J H M ， et al . Clinical pharmacokinetics of therapeutic monoclonal antibodies [J ] . Clin Pharmacokinet ， 2010 ， 49 （ 8 ）： 493 - 507 .

HERRSTEDT J ， ROILA F ， WARR D ， et al . 2016 updated MASCC/ESMO consensus recommendations：prevention of nausea and vomiting following high emetic risk chemotherapy [J ] . Support Care Cancer ， 2017 ， 25 （ 1 ）： 277 - 288 .

GRIFFITHS E A ， ROY V ， ALWAN L ， et al . NCCN guidelines ® insights：hematopoietic growth factors，version 1，2022 [J ] . J Natl Compr Cancer Netw ， 2022 ， 20 （ 5 ）： 436 - 442 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

Antithrombotic therapy and pharmaceutical care of a child with purpura nephritis complicated with lower extremity deep venous thrombosis

Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation

Pharmacy practice of clinical pharmacists involved in the treatment of a case of bullous pemphigoid and pulmonary aspergillosis combined with disseminated Nocardia farcinica infection

Multimodal analgesia in the treatment of a case of pediatric primary erythromelalgia with infection and pharmaceutical care

Related Author

HUO Meng

CHENG Qijian

LIN Jiayuan

LIU Weiting

LI Boxia

CHANG Yaowen

ZHANG Chunyan

HUANG Lin

Related Institution

Dept. of Pulmonary & Critical Care Medicine， Ruijin Hospital， Shanghai Jiao Tong University School of Medicine

Dept. of Pharmacy， Ruijin Hospital， Shanghai Jiao Tong University School of Medicine

Dept. of Pharmacy， the First Affiliated Hospital of Wenzhou Medical University

Dept. of Interventional Medicine， the First Hospital of Lanzhou University

Dept. of Pharmacy， the First People’s Hospital of Lanzhou

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰